Thailand Opioid Market Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

Thailand Opioid Market Overview

• The Thailand Opioid Market is valued at USD 1.1 billion, based on a five-year historical analysis and alignment with regional opioid market benchmarks in Asia Pacific, where demand is rising but remains moderate compared to North America and Europe. This growth is primarily driven by the increasing prevalence of chronic pain conditions, cancer, and the rising demand for effective pain management solutions, consistent with broader Asia Pacific trends in opioid utilization. The market is also influenced by the expanding healthcare infrastructure, universal health coverage, and the gradual integration of opioids into standardized pain management guidelines in tertiary and oncology centers in Thailand.
• Key cities such as Bangkok, Chiang Mai, and Pattaya dominate the market due to their advanced healthcare facilities and higher patient populations. Bangkok, as the capital, serves as a hub for pharmaceutical companies and healthcare providers, with a concentration of tertiary and oncology hospitals that require opioid analgesics for cancer and post-surgical pain. Chiang Mai and Pattaya have seen increased medical tourism and specialized private hospitals, which support demand for pain management, including opioid medications as part of post-operative and palliative care protocols.
• In 2021, the Thai government revised and consolidated the Narcotics Code through the Narcotics Code, B.E. 2564 (2021), issued by the Office of the Council of State and enforced by the Ministry of Public Health and related agencies, which regulates the manufacture, prescription, dispensing, and distribution of opioids. This legislation aims to ensure the safe use of opioids while preventing misuse and addiction by classifying opioids as controlled narcotics, defining licensing requirements, and specifying record-keeping and storage obligations for healthcare facilities and pharmacies. The code mandates that authorized prescribers use special narcotic prescription forms, maintain detailed logs, and comply with inspection and reporting requirements, thereby enhancing monitoring of opioid prescriptions and promoting responsible prescribing practices in hospital and community settings.

Thailand Opioid Market Segmentation

By Drug Type:The market is segmented into various drug types, including natural opioids, semi-synthetic opioids, synthetic opioids, and combination formulations. In hospital and palliative care practice, natural opioids such as morphine and codeine remain the backbone of moderate-to-severe cancer pain treatment under World Health Organization pain ladder recommendations adopted in Thailand. Semi-synthetic and synthetic opioids, particularly fentanyl, methadone, and tramadol, are increasingly used for severe pain, anesthesia, and opioid substitution therapy, with tramadol widely prescribed in Asia Pacific due to its perceived lower abuse potential. The increasing awareness of pain management options, expansion of palliative care services, and a growing number of oncology and surgical patients in Thailand are driving demand across these drug types, while hospital protocols and national narcotic controls shape the mix between injectable and oral formulations.

By Application:The opioid market is also segmented by application, including cancer pain, post-surgical and traumatic pain, chronic non-cancer pain, palliative and end-of-life care, and others. Cancer pain management is a significant driver, as Thailand has experienced steady growth in cancer incidence and mortality, with opioids recommended as essential medicines for moderate-to-severe cancer pain. Post-surgical and traumatic pain represent another major application segment, supported by a high volume of surgical procedures in tertiary hospitals and medical tourism centers that rely on opioids as part of perioperative analgesia. Chronic non-cancer pain and palliative and end-of-life care are expanding segments as Thailand strengthens its palliative care network, integrates pain control into universal health coverage, and trains clinicians in multimodal pain management approaches that include carefully controlled opioid use.

Thailand Opioid Market Competitive Landscape

The Thailand Opioid Market is characterized by a dynamic mix of regional and international players. Leading participants such as Government Pharmaceutical Organization (GPO), Biopharm Chemicals Co., Ltd., Greater Pharma Co., Ltd., Siam Bheasach Co., Ltd., Bangkok Drug Co., Ltd., Atlantic Laboratories Corporation Ltd., T.O. Chemicals (1979) Co., Ltd., Pfizer (Thailand) Ltd., Johnson & Johnson (Thailand) Ltd., Sanofi (Thailand) Ltd., Novartis (Thailand) Ltd., AstraZeneca (Thailand) Ltd., Merck Ltd. (Thailand), Mundipharma (Thailand) Ltd., Takeda (Thailand) Ltd. contribute to innovation, geographic expansion, and service delivery in this space.

Thailand Opioid Market Industry Analysis

Growth Drivers

• Increasing Prevalence of Chronic Pain:Chronic pain affects approximately 20% of the Thai population, translating to around 14 million individuals. This rising prevalence is driven by an aging population, with about 20% of Thais projected to be over 60 years old in future. The demand for effective pain management solutions, including opioids, is expected to increase significantly, as healthcare providers seek to address the needs of this growing demographic, thereby driving market growth.
• Rising Demand for Palliative Care:The Thai government has recognized the importance of palliative care, with a reported increase in funding for related services by 30% in future. This funding aims to improve access to pain relief for terminally ill patients, leading to a higher demand for opioids. As palliative care becomes more integrated into the healthcare system, the opioid market is likely to expand, catering to the needs of patients requiring effective pain management.
• Expanding Healthcare Infrastructure:Thailand's healthcare expenditure is projected to reach THB 1.5 trillion (approximately USD 45 billion) in future, reflecting a 10% increase from previous levels. This expansion includes the development of hospitals and clinics, particularly in underserved areas. Improved healthcare infrastructure facilitates better access to opioid prescriptions and pain management services, thereby driving the growth of the opioid market as healthcare providers become more equipped to manage chronic pain effectively.

Market Challenges

• Regulatory Restrictions on Opioid Prescriptions:Thailand has stringent regulations governing opioid prescriptions, with only 5% of healthcare providers authorized to prescribe these medications. This limitation is a significant barrier to access for patients in need of pain relief. The regulatory environment is influenced by concerns over misuse and addiction, which complicates the prescribing process and restricts the availability of opioids in the market.
• Stigma Associated with Opioid Use:There is a prevalent stigma surrounding opioid use in Thailand, with 60% of the population expressing concerns about addiction. This societal perception discourages patients from seeking necessary pain management solutions. Healthcare providers also face challenges in prescribing opioids due to fear of backlash from patients and families, which ultimately hinders the growth of the opioid market and limits access to effective treatments.

Thailand Opioid Market Future Outlook

The Thailand opioid market is poised for significant transformation as healthcare policies evolve to address pain management more effectively. With an increasing focus on personalized medicine and the integration of technology in treatment protocols, the market is likely to see innovative approaches to opioid use. Additionally, the expansion of telemedicine services will enhance access to pain management solutions, particularly in rural areas, fostering a more inclusive healthcare environment for patients suffering from chronic pain.

Market Opportunities

• Development of New Opioid Formulations:There is a growing opportunity for pharmaceutical companies to invest in the development of new opioid formulations that minimize addiction risks. Innovations such as abuse-deterrent formulations can cater to the needs of patients while addressing regulatory concerns, potentially increasing market acceptance and usage among healthcare providers.
• Expansion of Telemedicine for Pain Management:The rise of telemedicine presents a unique opportunity to enhance access to pain management services. With an estimated 30% of the population lacking access to specialized pain care, telemedicine can bridge this gap, allowing patients to receive consultations and prescriptions remotely, thus driving opioid market growth in underserved regions.